Innate Pharma (IPHA) Projected to Post Earnings on Thursday

Innate Pharma (NASDAQ:IPHA) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Innate Pharma to post earnings of ($0.3492) per share and revenue of $1.96 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 AM ET.

Innate Pharma Price Performance

Shares of NASDAQ IPHA opened at $1.31 on Thursday. Innate Pharma has a fifty-two week low of $1.31 and a fifty-two week high of $2.63. The business has a 50-day simple moving average of $1.69 and a two-hundred day simple moving average of $1.84.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in IPHA. Millennium Management LLC acquired a new position in shares of Innate Pharma during the fourth quarter valued at approximately $36,000. OLD Mission Capital LLC purchased a new position in shares of Innate Pharma in the fourth quarter valued at approximately $50,000. Finally, Jane Street Group LLC acquired a new stake in shares of Innate Pharma in the fourth quarter worth approximately $162,000. 0.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on IPHA shares. BTIG Research began coverage on Innate Pharma in a research note on Thursday, March 12th. They set a “buy” rating and a $8.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.